Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Conditions:   KRAS Gene Mutation;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer AJCC v7 Interventions:   Drug: Methotrexate;   Other: Pharmacokinetic Study;   Drug: Regorafenib Sponsor:   Stanford University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials